A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer

Lapatinib is approved in combination with capecitabine for treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who have progressed on prior trastuzumab in the metastatic setting. Vinorelbine is an important chemotherapy option for MBC. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Janni, Wolfgang, Sarosiek, Tomasz, Karaszewska, Boguslawa, Pikiel, Joanna, Staroslawska, Elzbieta, Potemski, Piotr, Salat, Christoph, Brain, Etienne, Caglevic, Christian, Briggs, Kathryn, DeSilvio, Michelle, Marini, Luca, Papadimitriou, Christos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907671/
https://www.ncbi.nlm.nih.gov/pubmed/24402830
http://dx.doi.org/10.1007/s10549-013-2828-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907671/
https://www.ncbi.nlm.nih.gov/pubmed/24402830
http://dx.doi.org/10.1007/s10549-013-2828-z

Ejemplares similares